what we do?

Rooted in science

sourced worldwide

LianBio is a biotechnology company focused on bringing paradigm-shifting medicines to patients.


Scroll to see more



Our Mission

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.

Learn More


Our Future

We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.

See All

Stay up to date

News & Events

March 29, 2021

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease


March 18, 2021

LianBio Announces Appointment of Yi Larson as Chief Financial Officer


March 2, 2021

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China


December 1, 2020

LianBio Announces Clearance to Initiate in China the Phase 2a Trial of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma with FGFR2 Gene Amplification

See All

We are here for you

Contact Us

Email us directly:

IR@LianBio.com careers@lianbio.com

Office Addresses

Shanghai Office
9th Floor, Kerry Parkside, 1155 Fangdian Road
Unit 901-902
Shanghai, PRC 201204

New Jersey Office
103 Carnegie Center Drive
Suite 215
Princeton, NJ 08540